1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
|
|
|
- けいしょう やまがた
- 9 years ago
- Views:
Transcription
1 ) 4) ) ) ) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer (PPI) 1 2 PPI PPI 3 1 ph 4 5 1) 5) 2 5
2 1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) c) β d) ACE ARB e) UKPDS LDL HbA1c a,b b,c c,d d,e a,e b,d 4) a) β 3 1 b) c) BMI 25 d) BMI e) Kcal/ a,b b,c c,d d,e a,e b,d 5) a) RA 130/80mmHg b) RA β c) d) 130/85mmHg e) a,b b,c c,d d,e a,e b,d
3 1 5 1) 2) 3) 4) 5) 40mL/min 12µg/mL mg/hr 120mL/min 200mg AUC 2.0mg min/ml % A 1 120mg 2 A CLcr Cockcroft-Gault A A CLcr CLcr 100mL/min (kg) 80 mg/dl 2.5
4 A V max K m 200mg/day 10mg/L A 6 A 10mg/L A 1 (mg)5 GFR 15mL/min 40mg 2 GFR=100mL/min X 1 X 40mg 20mg 4 X X 15L/hr 2L/hr cm 50kg 1.5m2 TNM T1N3M0 C A) C) 3 5 FEC100 (EPI) 100 mg/m 2 (CPA) 500 mg/m 2 (5-FU) 500 mg/m A) 1 B)4 C) 250mg / 5mL 1 ml
5 SRC SNP 19 ABL BCR PPAR KCNQ1 TCF7L2TNF p-loop
6 ATP GTP A D Ligation ----/AATT GATC/ TTAA/ /CTAG---- EcoR1 BamH1 A B C D RNA DNA DNA PCR DNA SV40 T EIA EIB SV40 T RB p53 DNA RNA GCP
7 GCP GCP
8
9
10 ( ) ( ) ( ) ( ) ( ) 薏
11 薏 ( ) 瘀 ( ) 芎 ( ) ( ) ( )
12 % %
13 A 3mL 14 B 3g C 3g 10 D 3cap 7 E 10g 1 2
14 % 2 A 1mL 8.70 B 1g C 1g D 1cap E 1g 3.50 OTC OTC OTC 7
15 OTC moist wound-healing therapy
16 a l
17 a. b. c. d. e f. g. h. DS20% 180mg mg 3g 10 30g mg DS20% g 14 g mg 1 14 g g
18 1 20 ( %) (1 ) ( ) 10 2 ( ) 30 ( ) (1 ) (4 ) 1 7( 5 ) 8 14 ( 4 ) () 21 1 (4 ) (4 ) () 26 1 (4 ) (1 ) 1 (1 ) ( 8 6 ) ( + ) % ( ) ( + ) 140% (22 6 ) ( + ) 200% ( 1 ) 7 ( 1 ) 8 40 ( ) ( ) ( 7 ) (1 1 ) 1 () 30 ( ) ( ) ( ) ( 1 4 ) () 15 1( 1 ) 2 1 () ( 1 ) ( 4 )( 2 8 ) 1() 2() ( 4 ) ( 2 ) ( 1 ) ( 1 ) ( 1 ) ( ) ( ) ( 1 1 ) /7
19 β Ca WPW LDL 1 mg/dl TG 2 mg/gl HDL 3 mg/dl LDL LDL = g 7 200mg/dL 8 126mg/dL AST ALT PT-INR ng/ml cm 64.8kg 1.5mg/dL 17 ml/min
20 SOAP GLUT4 PCI
21
22 1 1mL 1g O/W 3 W/O
23
24 ) 75 % 2) % 3) 75 4) ) 6) 7) 8) 9) 10) 11) 12) 13) 14)
25 1) 2) % 40% % 3) 1) 40 2) % 30% % 3) ) 5) 6) 1) 2) 3) 4) 1) 2) 3) 4) 1) 2) 5m 2
26 3) 1) DPC 2) DPC ) DPC 10 1) ) 68 3) 10 4) 5) 6) 500µg mg mg ) 500µg ) 35mg ) 20mg
27 2 ρ 318/1,607 (19.80%) 364/1,564 (23.30%) $72.20 $ ) RR 2) ICER A A B C QALY QALY WTP
28 (A) (B) (C) Oddi (D) 5-HT 4 (E) (F) H 2 (G) NSAID PGE 2 (H) C (I) COX-2 NSAID (J) (A) (B) (C) 1 DIC (D) (E) N-
29 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) 3 1 ( 1 ) (2x10 ) (A) 1) 2) 3) 4) 5) (B) (DIC) 1) 2) 3) 4) 5) (C) 1) 2) 3) 4) 5) (D) (SLE) 1) IgG 2) 3) 4) 5) TNF-α (E) 1) 2) 3) 4) 5) (F) 1) 2) 3) 4) 5) (G) 1) 2) 3) 4) 5)
30 (H) 1) 2) 3) 4) 5) (I) 1) 2) 3) 4) 5) (J) 1) 2) 3) 4) 5) 4. 1 ( ) (2x10 ) (A) a. b. c. d. e. 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e) (B) a. b. c.nsaid d. e. 1(a, b) 2(a, c) 3(a, d) 4(a, e) 5(b, c) 6(b, d) 7(b, e) 8(c, d) 9(c, e) 10(d, e)
31 (C) SLE a b. DNA III c. d. e. 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e) (D) a. ph b. c. 13 C d. 2 PPI 3 e. 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e) (E) a.60 b. c. d. e. 1(a, b) 2(a, c) 3(a, d) 4(a, e) 5(b, c) 6(b, d) 7(b, e) 8(c, d) 9(c, e) 10(d, e) (F) a. Fisher b.a c. 1 1 d. e. C
32 1(a, b) 2(a, c) 3(a, d) 4(a, e) 5(b, c) 6(b, d) 7(b, e) 8(c, d) 9(c, e) 10(d, e) (G) B a. HBV b.hbv HBs c.hiv d.hbs HBV e.a 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a, c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c, e) 9(b, d, e) 10(c, d, e) (H) a. b. c. d. ALT<AST e. 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e) (I) a. b. c. d. e. β 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e)
33 (J) a. b. CO 2 c. d. e. 1(a, b, c) 2(a, b, d) 3(a, b, e) 4(a. c, d) 5(a, c, e) 6(a, d, e) 7(b, c, d) 8(b, c e) 9(b, d, e) 10(c, d, e) 5. ( ) 2 (2 10 ) (A) ( ) ( ) ( ) ( )( ) (B) 1 ( ) ( ) ( ) 2 (C) ( ) (D) (TAE)(PEI) (RFA) ( )
34 a:1,2 b:2,3 c:3,4 d:4,5 e:1,5 f:1,3 g:2,4 1. WHO a:1,2 b:2,3 c:3,4 d:4,5 e:1,5 f:1,3 g:2, ~15mg/ ~ a:1,2 b:2,3 c:3,4 d:4,5 e:1,5 f:1,3 g:2,4
35 a:1 b:2 c:3 d:4 e:5 f: cm a:1,2 b:2,3 c:3,4 d:4,5 e:1,5 f:1,3 g:2,4 66 SU SU a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 1.2g GFR60mL/ a: b: c: d: e: 140/80mmHg 76/ 2-20 MRI 300mg/dL ph7.1 PaO 2 92mmHg PaCO 2 32mmHg a: b: c: d: e:
36 1 PaO 2 2 PaCO a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 a 150/90mmHg b 140/85mmHg c 130/80mmHg d 125/75mmHg e 120/70mmHg a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5 66 OTC 70/46mmHg 120/ / a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 WBC 7600/µL( ) RBC 240 /µl( ) 6.4g/dL(12-16) 20%(35-47) BUN 46mg/dL(8-20) Cr 0.8mg/dL( ) a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5
37 a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5 48 LDL 180mg/dL (H-FABP) a:st b:st c: d: e: 116/76 84/ a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4, K 5 a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 a: b: c: d: e: c,d,e Na 4 K 5 a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5
38 a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4, a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 160/82mmHg 1 tpa a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5 ph7.56 PaO 2 78mmHg PaCO 2 40mmHg a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 1 Ca 2 P 3 Cl 4 K 5 Na a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3, a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5
39 a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5 CKD egfr 35mL/ a: 1 b: 2 c: 3 d: 4 e: 5 egfr a: essential glomerular filtration rate b: essential glomerular function rate c: essential glomerular filtration rank d: estimated glomerular filtration rate e: estimated glomerular function rate BUN 4 5 a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3, a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3, β a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5
40 2 camp 3 cgmp 4 adenylate cyclase 5 a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 180/ cm 90KgK 2.8mEq/L a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5 110 / 64mmHg a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3, /56mmHg NSAIDs 5 a:1 b:2 c:3 d:4 e:5 f:1,2 g:1,5 h:2,3 i:3,4 j:4,5 DIC FDP a:1,2 b:1,5 c:2,3 d:3,4 e:4,5 f:1,2,3 g:1,2,5 h:2,3,4 i:3,4,5 j:1,3,5
41 A mL/min A A GFR 125mL/min GFR = 20 ml/min P = 10 µg/ml U = 200µg/mL V = 2.0 ml/min R = 20 % (ml/min) (µg/min) 1.2L/min 20% (%) 1.5L/min 9L/hr ng/mL 501 (mg)
42 70kg 400mg 1L 4µg/mL (ml/min) 10mL/min/kg 250mg/day 15µg/mL Michaelis-Menten V max 400 mg/day V max 300mg/day 250mg/day µg/ml A100mg (AUC) 400µg min/ml mg 100% AUC(µg min/ml) 1.5L/min A Michaelis-Menten V max =200mg/hr Km=10µg/mL A 100mg/hr 150mg/hr K 6 K 100mg 6 2.5µg/mL K 1 100mg 1 4 µg/ml 100mg K 45 K 0.5 K %
62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -
![62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -](/thumbs/41/22310901.jpg "62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -")
1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /
[] 1
![[] 1](/thumbs/42/22960844.jpg "[] 1")
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5
Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
取扱説明書 ［F-02F］
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
LDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
001-029_”÷’X
54 2012 1 29 Kimori Daisuke Kamijo Takashi Takahashi Akira 1993 19951997 2001 10 1993 1999 1992 54 2012 1993 20 LDH BUNCRE UA CPK GOT CPK LDH UA CPK LDH UA CPK 1989 2001 2000 1989 1995 2003 2005 1989 54
1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
橡DI月報１７8.PDF
2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
生化学検査 臨床検査基準値一覧 近畿大学病院 (1) 検査項目 基準値 単位 検査項目 基準値 単位 CRP mg/dl WBC /μl Na mmol/l M RBC K mmol/l F 3.86-
生化学検査 近畿大学病院 (1) CRP 0.00-0.14 WBC 3.3-8.6 10 3 /μl Na 138-145 mmol/l M 4.35-5.55 RBC K 3.6-4.8 mmol/l F 3.86-4.92 10 6 /μl Cl 101-108 mmol/l M 13.7-16.8 HGB g/dl Ca 8.8-10.1 F 11.6-14.8 Pi 2.7-4.6 液 M
日本呼吸器学会雑誌第47巻第6号
Fig.1 A,ChestX-rayfilm demonstratingatumorshadow intherightlowerlungfield.b,chestct scan demonstratingtherightmiddlelobemass,measuring9.0 7.3cm.C,AbdominalCT scanshowingfree airintheabdominalcavityanddirtyfatsignaroundthesigmoidcolontumor.
136 pp p µl µl µl
135 2006 PCB C 12 H 10-n Cl n n 1 10 CAS No. 42 PCB: 53469-21-9, 54 PCB: 11097-69-1 0.01 mg/m 3 PCB PCB 25 µg/l 136 pp p µl µl µl 137 1 γ 138 1 γ γ γ µl µl µl µl µl µl µl l µl µl µl µl µl l 139 µl µl µl
コロイド化学と界面化学
x 25 1 kg 1 kg = 1 l mmol dm -3 ----- 1000 mg CO 2 -------------------------------------250 mg Li + --------------------------------1 mg Sr 2+ -------------------- 10
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
日本呼吸器学会雑誌第44巻第7号
Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %
HITACHI 液晶プロジェクター CP-AX3505J/CP-AW3005J 取扱説明書 -詳細版- 【技術情報編】
B A C E D 1 3 5 7 9 11 13 15 17 19 2 4 6 8 10 12 14 16 18 H G I F J M N L K Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
取扱説明書 -詳細版- 液晶プロジェクター CP-AW3019WNJ
B A C D E F K I M L J H G N O Q P Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01 00 00 60 01 00 BE EF 03 06 00 19 D3 02 00
合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
<8C9F8DB85F3338E4508CB495612E786C73>
尿 検 査 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり 随 時 尿 蛋 白 ( 定 性 ) - - - 糖 ( 定 性 ) - - - 潜 血 ( 定 性 ) - - - 項 目 に が 付 与 されている 場 合 : 該 当 の 項 目 は 1/5 尿 検 査 血 球 算 定 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり WBC ( )
12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
C VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min
6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3